In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cangene Corp.

Division of Emergent BioSolutions Inc.

Latest From Cangene Corp.

Pharma's Love Affair With Dealmaking: No End In Sight

The pace of pharma dealmaking continued unabated in 2015, climaxing with Pfizer’s agreed $160 billion merger with Allergan. Conditions are right for this situation to persist, at least for the foreseeable future.

BioPharmaceutical Deals

CBER Approvals Hit A High Note For Director Midthun's Swan Song

Twelve novel biologics in 2015 sets record, with 'biobetter' coagulation factors again making up largest group of new products.

BioPharmaceutical United States

Keeping Track: Kybella, Ixinity, Raplixa Approved; Three 'Complete Responses' Surprise No One

The latest drug development news and highlights from our FDA Performance Tracker.

BioPharmaceutical Regulation

Deals Shaping The Medical Industry, February 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced December 2013 through January 2014.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Emergent BioSolutions Inc.
  • Senior Management
  • John A Sedor, Pres. & CEO
    Jeff Lamothe, CFO
    Laura Saward, PhD, CSO
    Chris Sinclair, VP, Bus. Dev. & Corp. Strategic Planning
    Michael Adelman, VP, Commercial Operations
  • Contact Info
  • Cangene Corp.
    Phone: (204) 275-4200
    155 Innovation Dr.
    Winnipeg, R3T 5Y3